CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chairman of InVivo’s Board of Directors, effective immediately. Perrin has served as a Board member and Chief Executive Officer of the company since January 2014. John A. McCarthy, Jr., current non-executive Chairman of the Board since September 2013, will remain on the Board and will continue to chair the Audit Committee.
“Given the significant transformation of the company over the past year under Mark’s leadership as CEO, the Board and I felt it was appropriate timing to now unify the Chairman and CEO roles, “ stated John McCarthy. “Our decision was made to promote consistent and unified leadership, timely decision-making, strategy development, and execution.”
“I look forward to taking on the challenges of Board chair,” Mark Perrin said, adding that the entire Board wishes to acknowledge John’s significant contributions over the past transformative year. “We all appreciate John’s broad input and expertise, and we know his support for InVivo’s future will be important as we move ahead with the Neuro-Spinal Scaffold and other development programs.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
